Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
Blood|April 20, 2021
14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemiaDanika Di Giacomo, Roberta La Starza, Paolo Gorello, et al.
Annals of Hematology|September 21, 2023
A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working GroupGregorio Barilà, Francesca Maria Quaglia, Anna Furlan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 6, 2016
Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term OutcomeFederico Lussana, Tamara Intermesoli, Francesca Gianni, et al.
Blood|January 15, 2009
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)Renato Bassan, Orietta Spinelli, Elena Oldani, et al.
Cancers|August 16, 2020
High Throughput Molecular Characterization of Normal Karyotype Acute Myeloid Leukemia in the Context of the Prospective Trial 02/06 of the Northern Italy Leukemia Group (NILG)Silvia Salmoiraghi, Roberta Cavagna, Pamela Zanghì, et al.
Internal and Emergency Medicine|January 15, 2015
Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemiaAndrea Piccin, Michael Steurer, Manfred Mitterer, et al.
Blood Advances|April 6, 2019
Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AMLRenato Bassan, Tamara Intermesoli, Arianna Masciulli, et al.
The New England Journal of Medicine|March 2, 2017
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic LeukemiaHagop Kantarjian, Anthony Stein, Nicola Gökbuget, et al.
Leukemia|November 18, 2025
Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpointFausto Castagnetti, Massimo Breccia, Elisabetta Abruzzese, et al.
Blood Advances|June 5, 2023
Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trialRenato Bassan, Sabina Chiaretti, Irene Della Starza, et al.
Pageof 8